Effects of Maqui Supplementation on Gut Microbiota, Inflammation, and Oxidative Stress in Patients With Chronic Kidney Disease
In plain words A study of maqui Berry in people 45 to 75, run by Universidad Mayor. It plans to enroll about 30 people at 1 site, none in the US.
Who it lists and where
Who the trial lists, as registered
Lists people 45 to 75. Conditions: Chronic Kidney Disease (Stage 3-4).
- Men and women.
- Age between 40 and 75 years.
- Normal weight or overweight nutritional status.
- Regular attendance at healthcare follow-up visits.
1 more inclusion criterion and the exclusion criteria are on the listing.
What it tests, as registered
maqui supplementation; PLA
Registered summary
Chronic kidney disease (CKD) is a highly prevalent condition in Chile and worldwide and is associated with a substantial burden of morbidity, particularly cardiovascular morbidity. In the early stages of CKD, treatment aims to preserve kidney function and slow the progression of associated complications. Several conditions have been reported in association with CKD, including impaired antioxidant capacity, inflammation, and alterations in the gut microbiota (GM), which contribute, among other complications, to the loss of kidney function and cardiovascular damage. The full summary is on the listing.
Where, as registered
No US site; Chile (1).